Barclays
WGS icon

Barclays’s GeneDx Holdings WGS Stock Holding History

Barclays’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$505K Sell
7,864
-26,072
-77% -$2.38M ﹤0.01% 3182
2025
Q4 		$4.41M Sell
33,936
-12,044
-26% -$1.65M ﹤0.01% 2314
2025
Q3 		$4.95M Sell
45,980
-13,425
-23% -$1.46M ﹤0.01% 2204
2025
Q2 		$5.48M Sell
59,405
-15,475
-21% -$1.21M ﹤0.01% 2044
2025
Q1 		$6.63M Sell
74,880
-5,527
-7% -$479K ﹤0.01% 1701
2024
Q4 		$6.18M Buy
80,407
+61,486
+325% +$4.29M ﹤0.01% 1961
2024
Q3 		$803K Buy
18,921
+14,681
+346% +$496K ﹤0.01% 3501
2024
Q2 		$111K Buy
+4,240
New +$80.4K ﹤0.01% 3857
2023
Q2 		– Sell
-5,318
Closed -$64.1K – 5121
2023
Q1 		$64.1K Buy
5,318
+4,032
+314% +$53.8K ﹤0.01% 4363
2022
Q4 		$11.2K Buy
1,286
+1,083
+533% +$23.9K ﹤0.01% 4907
2022
Q3 		$6K Sell
203
-333
-62% -$15.2K ﹤0.01% 4476
2022
Q2 		$22K Buy
536
+212
+65% +$14.4K ﹤0.01% 4362
2022
Q1 		$33K Buy
+324
New +$36K ﹤0.01% 4278

Other funds holding WGS

CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays's WGS Position: Q1 2026 in Review

Barclays reduced its GeneDx Holdings (WGS) stake by 77% in Q1 2026, selling an estimated $2.38M and leaving 7,864 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #3182.

Barclays first reported a position in WGS in Q1 2022 and has held it in 13 quarters since. The position peaked at $6.63M in Q1 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • Barclays held 7,864 shares of GeneDx Holdings worth $505K as of Q1 2026.
  • Barclays sold 26,072 GeneDx Holdings shares in Q1 2026, an estimated $2.38M.
  • GeneDx Holdings made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3182 holding.
  • Barclays first reported a position in GeneDx Holdings in Q1 2022 and has held it in 13 quarters since.
  • Barclays's GeneDx Holdings position peaked at $6.63M in Q1 2025.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.